Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. 2011

Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
Dipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, Via del Liceo 1, 06123 Perugia, Italy. lbarreca@unipg.it

Chronic infection by hepatitis C virus (HCV) often leads to severe liver disease including cirrhosis, hepatocellular carcinoma and liver failure. Despite it being more than 20 years since the identification of HCV, the current standard of care for treating the infection is based on aspecific therapy often associated with severe side effects and low-sustained virological response. Research is ongoing to develop new and better medications, including a broad range of allosteric NS5B polymerase inhibitors. This article reviews traditional computational methodologies and more recently developed in silico strategies aimed at identifying and optimizing non-nucleoside inhibitors targeting allosteric sites of HCV NS5B polymerase. The drug-discovery approaches reviewed could provide take-home lessons for general computer-aided research projects.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus
D017076 Computer-Aided Design The use of computers for designing and/or manufacturing of anything, including drugs, surgical procedures, orthotics, and prosthetics. CAD-CAM,Computer-Aided Manufacturing,Computer-Assisted Design,Computer-Assisted Manufacturing,Computer Aided Design,Computer Aided Manufacturing,Computer Assisted Design,Computer Assisted Manufacturing,Computer-Aided Designs,Computer-Assisted Designs,Design, Computer-Aided,Design, Computer-Assisted,Designs, Computer-Aided,Designs, Computer-Assisted,Manufacturing, Computer-Aided,Manufacturing, Computer-Assisted
D017361 Viral Nonstructural Proteins Proteins encoded by a VIRAL GENOME that are not structural components of VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY. Nonstructural Proteins, Viral,NS Proteins, Viral,Viral NS Proteins,Viral Non-Structural Proteins,Viral Nonstructural Protein,Viral Nonstructural Proteins NS1,Viral Nonstructural Proteins NS2,Nonstructural Protein, Viral,Viral Non Structural Proteins
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
March 2006, Infectious disorders drug targets,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
March 2020, Journal of biomolecular structure & dynamics,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
August 2017, Bioorganic & medicinal chemistry letters,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
October 2020, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
December 2017, Virology journal,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
May 2008, Bioorganic & medicinal chemistry letters,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
February 2010, Bioorganic & medicinal chemistry letters,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
March 2014, Journal of medicinal chemistry,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
March 2014, Journal of medicinal chemistry,
Maria Letizia Barreca, and Nunzio Iraci, and Giuseppe Manfroni, and Violetta Cecchetti
December 2004, Journal of medicinal chemistry,
Copied contents to your clipboard!